Evidence map›Paper›PMID 30382763›Full record

ArticleCell cycle (Georgetown, Tex.)2018

Up-regulation of microRNA-497 inhibits the proliferation, migration and invasion but increases the apoptosis of multiple myeloma cells through the MAPK/ERK signaling pathway by targeting Raf-1.

Cheng-Yu Ye, Cui-Ping Zheng, Wei-Wei Ying, Shan-Shan Weng

RetractedOpen access · bronzeAbstract readRetracted Publication
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. The Role of MiRNA in Cancer: Pathogenesis, Diagnosis, and Treatment.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  4. Review
  5. Role of FAT1 in health and disease.Oncology letters · 2021
    Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Cheng-Yu Yea Department of Hematologic Oncology , Wenzhou Central Hospital, Dingli Clinical Medical School of Wenzhou Medical University , Wenzhou , P.R. China.
Cui-Ping Zhenga Department of Hematologic Oncology , Wenzhou Central Hospital, Dingli Clinical Medical School of Wenzhou Medical University , Wenzhou , P.R. China.
Wei-Wei Yingb Wenzhou Medical University , Wenzhou , P.R. China.
Shan-Shan Wenga Department of Hematologic Oncology , Wenzhou Central Hospital, Dingli Clinical Medical School of Wenzhou Medical University , Wenzhou , P.R. China.
Wenzhou Central Hospital · CNWenzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple myeloma (MM) is a cancer that occurs in plasma cells, which fall under the category of white blood cells that are in charge of antibody production. According to previous studies, microRNA-497 (miR-497) functions as a tumor suppressor in several types of cancer, including gastric cancer and colorectal cancer. Therefore, the present study aims to investigate the effects of miR-497 on cellular function of human MM cells through the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway by targeting Raf-1. The differentially expressed genes and miRs in MM, and the relationship between the miR and gene were verified. It was found that Raf-1 was a target gene of miR-497. The data obtained from MM tissues showed increased Raf-1 level and decreased miR-497 level. MM cells were treated with mimic, inhibitor and siRNA in order to evaluate the role of miR-497, Raf-1 and MAPK/ERK in MM. The expression pattern of miR-497, Raf-1, ERK1/2, survivin, B-cell lymphoma-2 (Bcl-2) and BCL2-Associated X (Bax) as well as the extent of ERK1/2 phosphorylation were determined. Retored miR-497 and si-Raf-1 resulted in increases in the Bax expression and cell apoptosis and decreases in the expressions of Raf-1, MEK-2, survivin, Bcl-2, along with the extent of ERK1/2 phosphorylation. In addition, the biological function evaluations of MM cells revealed that miR-497 mimic or si-Raf-1 led to suppression in cell proliferation, invasion and migration. In conclusion, our results have demonstrated that miR-497 targets Raf-1 in order to inhibit the progression of MM by blocking the MAPK/ERK signaling pathway.

Indexed as

AnimalsAntagomirsCell Line, TumorCell MovementCell ProliferationFemaleHumansMaleMAP Kinase Signaling SystemMiceMice, NudeMicroRNAsMiddle AgedMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Multiple MyelomaAntagomirsMicroRNAsMIRN497 microRNA, humanMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Proto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-rafRaf1 protein, humanRNA, Small InterferinginvasionMAPK/ERK signaling pathwayMicroRNA-497migrationmultiple myelomaproliferationRaf-1

Identifiers

PMID30382763
PMCPMC6343711
OpenAlexW2898863009

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.